Predictive Oncology Inc. announced that J. Melville (“Mel”) Engle will retire as Chairman and a member of the company's Board of Directors. To ensure a smooth transition of his responsibilities, Mr. Engle will continue to serve in his role through October 31, 2022. Mr. Engle, 72, has been with POAI since 2016, when he joined the Board of Directors.

He was appointed Chairman of the Board in January 2020 and was named Chief Executive Officer in March 2021. He has played an instrumental role in the company's growth as it has evolved as a partner to pharmaceutical and biotech companies involved in oncology drug development. Under his guidance, Mr. Engle has helped expand the company's offerings to become a suite of solutions along the drug development continuum, from early discovery to clinical trials.